DBV Technologies S.A.'s SEC filings document a foreign issuer reporting framework for ordinary shares and American Depositary Shares. Form 8-K reports furnish financial results and business highlights, disclose registered securities, and record material governance and compensation actions.
Proxy materials for DBV Technologies S.A. cover shareholder voting matters, board authorization, compensation committee recommendations and equity award authority under French corporate law. The filings also identify ADS terms in which each American Depositary Share represents five ordinary shares, with the ADSs registered on Nasdaq under DBVT.
DBV Technologies S.A. director Philina Lee filed an initial Form 3, which is a required statement of her beneficial ownership as an insider of the company. The filing shows no reportable transactions in the company’s securities at this time.
DBV Technologies S.A. director Philina Lee filed an initial Form 3, which is a required statement of her beneficial ownership as an insider of the company. The filing shows no reportable transactions in the company’s securities at this time.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.
DBV Technologies reported full-year 2025 results showing continued investment ahead of a potential launch of its VIASKIN® Peanut Patch. Under U.S. GAAP, operating income was $5.6 million for the year ended December 31, 2025, up from $4.2 million in 2024, mainly from higher French research tax credits.
Research and development expenses rose to $116.7 million, while general and administrative expenses increased to $32.8 million, reflecting clinical progress and launch preparation. Net loss widened to $147.0 million versus $113.9 million in 2024, though net loss per share improved to $1.05 from $1.17. Including $94 million of warrant-related proceeds received in January 2026, management expects existing cash and cash equivalents to fund operations into the second quarter of 2027, based on current plans focused on the VIASKIN Peanut Patch.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform for food allergies, led by Viaskin Peanut. The patch delivers tiny doses of allergen through intact skin to Langerhans cells, aiming to desensitize patients while limiting systemic exposure.
Viaskin Peanut has shown positive Phase 3 results in toddlers (EPITOPE/EPOPEX) and children 4–7 years (VITESSE), with statistically significant increases in tolerated peanut dose and mainly local skin reactions. The company plans Biologics License Application submissions in the first and second half of 2026 for children 4–7 and 1–3 years old, including an FDA Accelerated Approval pathway for toddlers supported by the COMFORT Toddlers safety study.
DBV also pursues Viaskin Milk and earlier programs, but depends heavily on Viaskin Peanut. It reports a history of significant losses, potential future funding needs, extensive clinical and regulatory risk, manufacturing reliance on partners such as Sanofi and Fareva, intellectual property dependencies, and the risk of failing to maintain Nasdaq listing standards.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform for food allergies, led by Viaskin Peanut. The patch delivers tiny doses of allergen through intact skin to Langerhans cells, aiming to desensitize patients while limiting systemic exposure.
Viaskin Peanut has shown positive Phase 3 results in toddlers (EPITOPE/EPOPEX) and children 4–7 years (VITESSE), with statistically significant increases in tolerated peanut dose and mainly local skin reactions. The company plans Biologics License Application submissions in the first and second half of 2026 for children 4–7 and 1–3 years old, including an FDA Accelerated Approval pathway for toddlers supported by the COMFORT Toddlers safety study.
DBV also pursues Viaskin Milk and earlier programs, but depends heavily on Viaskin Peanut. It reports a history of significant losses, potential future funding needs, extensive clinical and regulatory risk, manufacturing reliance on partners such as Sanofi and Fareva, intellectual property dependencies, and the risk of failing to maintain Nasdaq listing standards.
DBV Technologies filed a report highlighting additional positive data from its successful Phase 3 VITESSE study of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years.
The trial met its primary endpoint, with 46.6% of children on VIASKIN Peanut classified as responders at 12 months versus 14.8% on placebo, a 31.8% difference in response rates (95% CI 24.5–39.0%, p<0.001). The company states these data support a planned Biologics License Application submission to the FDA in the first half of the year.
DBV Technologies filed a report highlighting additional positive data from its successful Phase 3 VITESSE study of the VIASKIN® Peanut Patch in peanut-allergic children aged 4 to 7 years.
The trial met its primary endpoint, with 46.6% of children on VIASKIN Peanut classified as responders at 12 months versus 14.8% on placebo, a 31.8% difference in response rates (95% CI 24.5–39.0%, p<0.001). The company states these data support a planned Biologics License Application submission to the FDA in the first half of the year.
DBV Technologies S.A. received an updated ownership report from a group of Venrock Healthcare-related funds and individuals, including VHCP II, VHCP III, VHCP EG, associated co-investment vehicles, management LLCs, and investors Nimish Shah and Bong Y. Koh. As of December 31, 2025, each reporting person discloses 0 ordinary shares beneficially owned, representing 0.0% of the class, with no sole or shared voting or dispositive power. They also certify the securities were not acquired or held to change or influence control of DBV Technologies.
DBV Technologies S.A. received an updated ownership report from a group of Venrock Healthcare-related funds and individuals, including VHCP II, VHCP III, VHCP EG, associated co-investment vehicles, management LLCs, and investors Nimish Shah and Bong Y. Koh. As of December 31, 2025, each reporting person discloses 0 ordinary shares beneficially owned, representing 0.0% of the class, with no sole or shared voting or dispositive power. They also certify the securities were not acquired or held to change or influence control of DBV Technologies.
DBV Technologies S.A. received an updated ownership report from a group of Citadel-affiliated entities and Kenneth Griffin on its ordinary shares. The filing states that Mr. Griffin may be deemed to beneficially own 8,146,510 shares, representing 3.5% of the company’s outstanding shares as of December 31, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 7,413,959 shares, or 3.1% of the class, while various Citadel Securities entities report smaller positions. All reported voting and dispositive powers are shared rather than sole. The reporting group certifies the holdings are not intended to change or influence control of DBV Technologies.
DBV Technologies S.A. received an updated ownership report from a group of Citadel-affiliated entities and Kenneth Griffin on its ordinary shares. The filing states that Mr. Griffin may be deemed to beneficially own 8,146,510 shares, representing 3.5% of the company’s outstanding shares as of December 31, 2025.
Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may each be deemed to beneficially own 7,413,959 shares, or 3.1% of the class, while various Citadel Securities entities report smaller positions. All reported voting and dispositive powers are shared rather than sole. The reporting group certifies the holdings are not intended to change or influence control of DBV Technologies.
BioImpact LLC reported a significant passive stake in DBV Technologies S.A., disclosing beneficial ownership of 24,579,307 Ordinary Shares as of December 31, 2025. This includes Ordinary Shares held directly, shares represented by American Depositary Shares (each ADS equals five Ordinary Shares), and Ordinary Shares underlying pre-funded warrants.
BioImpact’s position represents 9.99% of DBV’s Ordinary Shares, although EDGAR field limits show this as 9.9% on the cover page. The firm has sole voting and dispositive power over all reported shares and certifies that the holdings are for ordinary-course, non-control purposes.
BioImpact LLC reported a significant passive stake in DBV Technologies S.A., disclosing beneficial ownership of 24,579,307 Ordinary Shares as of December 31, 2025. This includes Ordinary Shares held directly, shares represented by American Depositary Shares (each ADS equals five Ordinary Shares), and Ordinary Shares underlying pre-funded warrants.
BioImpact’s position represents 9.99% of DBV’s Ordinary Shares, although EDGAR field limits show this as 9.9% on the cover page. The firm has sole voting and dispositive power over all reported shares and certifies that the holdings are for ordinary-course, non-control purposes.
DBV Technologies S.A. (DBVT) received an updated ownership report on its ordinary shares, represented by American Depositary Shares. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 15,685,950 ordinary shares, or 5.7% of the class, based on 274,852,082 ordinary shares outstanding as of February 9, 2026.
Separately, Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC report beneficial ownership of 2,014,280 ordinary shares, or 0.7% of the class. The filing states the securities are not held for the purpose of changing or influencing control of DBV Technologies.
DBV Technologies S.A. (DBVT) received an updated ownership report on its ordinary shares, represented by American Depositary Shares. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 15,685,950 ordinary shares, or 5.7% of the class, based on 274,852,082 ordinary shares outstanding as of February 9, 2026.
Separately, Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC report beneficial ownership of 2,014,280 ordinary shares, or 0.7% of the class. The filing states the securities are not held for the purpose of changing or influencing control of DBV Technologies.
DBV Technologies S.A. received an updated Schedule 13G/A from a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of December 31, 2025, they collectively reported beneficial ownership of 14,350,960 Ordinary Shares, equal to 6.2% of the company’s Ordinary Shares.
The position consists of Ordinary Shares and American Depositary Shares, with each ADS representing five Ordinary Shares. The filing attributes control of the various Invus and Avicenna entities up a chain to Raymond Debbane, who may be deemed to beneficially own the same 6.2% stake. The group certifies the holdings are not for the purpose of changing or influencing control of DBV Technologies.
DBV Technologies S.A. received an updated Schedule 13G/A from a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of December 31, 2025, they collectively reported beneficial ownership of 14,350,960 Ordinary Shares, equal to 6.2% of the company’s Ordinary Shares.
The position consists of Ordinary Shares and American Depositary Shares, with each ADS representing five Ordinary Shares. The filing attributes control of the various Invus and Avicenna entities up a chain to Raymond Debbane, who may be deemed to beneficially own the same 6.2% stake. The group certifies the holdings are not for the purpose of changing or influencing control of DBV Technologies.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 3,309,055 DBV Technologies S.A. American Depositary Shares, representing 7.0% of the class based on 47,134,173 shares outstanding as of 12/31/2025. The position is held for discretionary clients of Artisan Partners Limited Partnership.
Artisan reports no sole voting or dispositive power, with shared voting power over 2,976,900 shares and shared dispositive power over 3,309,055 shares. The firms state the securities were acquired and are held in the ordinary course of business, not to change or influence control of DBV Technologies.
Artisan Partners, through several affiliated Delaware entities, reports beneficial ownership of 3,309,055 DBV Technologies S.A. American Depositary Shares, representing 7.0% of the class based on 47,134,173 shares outstanding as of 12/31/2025. The position is held for discretionary clients of Artisan Partners Limited Partnership.
Artisan reports no sole voting or dispositive power, with shared voting power over 2,976,900 shares and shared dispositive power over 3,309,055 shares. The firms state the securities were acquired and are held in the ordinary course of business, not to change or influence control of DBV Technologies.